SESSION TITLE: Tobacco Cessation and Prevention
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Sunday, October 27, 2013 at 10:45 AM - 11:45 AM
PURPOSE: Review the results analyzed in a Tobacco Cessation Unit during 2008-2009.
METHODS: Retrospective descriptive analysis of the results obtained from patients who were attended in a Tobacco Cessation Unit from January 1st in 2008 to December 31 in 2009 and the subsequent follow-up to complete a year.
RESULTS: 559 of 838 patients, 53,7% male. S.s. between cigarettes smoked and sex, higher in males (29,48 vs. 24,78, p<0.01). Severe comorbidity: respiratory (34,1%), CVRF (56%) and psychiatric (37,7%). 32,7% without treatment, 34,5% NRT, 9,8% bupropion and 22,9% varenicline. Continuous abstinence rates at 3, 6, 9 and 12 months follow up for males were 51,3%, 37,7%, 32,5% and 30,5% respectively; continuous abstinence rates at 3, 6, 9 and 12 months follow up for females were 45,2%, 29,8%, 25% and 24,2%, respectively, and continuous abstinence rates at 3, 6, 9 and 12 months follow up for overall sample were 48,6%, 34,2%, 29,1% and 27,7%, respectively. Overall of the 559 patients, treatment success (one year without smoking) in 77 (13,8%), 47 men and 30 women; percentage rises to 27,7% if we do not consider those who did not attend the second consultation. Those who were treated pharmacologically, greater success among who used varenicline (5,7%) than NRT (5%) or bupropion (1,4%).
CONCLUSIONS: 1. 66,82% did not start treatment (33,3% and 33,52%, first and second appointment respectively). 2. Cigarette consumption by males was significantly higher than women (29,48 vs. 24,78, p<0,01). 3. Continuous abstinence rates were higher for males than females and overall treatment success was 27,7%. 4. Greater success among varenicline than NRT or bupropion-treated.
CLINICAL IMPLICATIONS: When patients attend our Tobacco Cessation Unit, they have often severe comorbidity. Smoking cessation treatment is effective but it requires patients commitment. There is an overall treatment success of 27,7% excluding those who did not attend the second consultation. In our sample, patients treated with varenicline showed a success rate higher than the ones treated with bupropion or nicotine replacement therapy.
DISCLOSURE: The following authors have nothing to disclose: Francisco Javier Callejas Gonzalez, Abel Martinez Garcia, Marta Genoves Crespo, Juan Pastrana Calderon, Mariela Plenc Ziegler, Angel Molina Cano, Sergio Garcia Castillo, Javier Cruz Ruiz, Juan Carlos Ceballos Romero, Ana Isabel Tornero Molina
No Product/Research Disclosure Information